Forecast Ledgerinterventional psychiatry and psychedelic medicineQuoted, dated predictions scored against public outcomes under one written method. Every score links to the words, the rule and the evidence.

Pending · due 5 Jun 2035

Rules 1.1.0 · as of 14 Sep 2026

Quote

“In my view, mental health will be the largest market in healthcare within 10 years — surpassing oncology and cardiology.”
· Christian Angermayer on X: It has always puzzled me how much big pharma has neglected mental health · tweet

Commenting on Ferring Pharmaceuticals taking a stake in $ATAI, he argues big pharma has neglected mental health and forecasts it becomes the largest healthcare market.

Intake

EventA proposition written from a template on the asset, with a resolution criterion and a named public source, before the outcome is looked up. The same event resolves every person's items on it. Method ›
Mental health becomes the largest therapeutic-area market in healthcare
AreaOne of five topic classes: regulatory decisions, clinical trial outcomes, company and market outcomes, payer and policy, practice adoption. Every event has one area. Method ›
Company and market outcomes
DeadlineThe date by which the event must happen for the item to be true. It comes only from the person's words through the anchor table. Method ›
5 Jun 2035 AnchorThe fixed table that turns the person's own words ('by 2026', 'Q2', 'within two years') into a deadline. The coder never invents a date. Method › · “within 10 years”
Probability
0.90 LexiconThe fixed five-bin table that turns a phrase into a probability. The strongest phrase in the claim sentence decides; coders never read tone. Method › · binOne of five lexicon steps: A 'will' 0.90, B 'probably' 0.70, C 'may' 0.50, D 'unlikely' 0.30, E 'never' 0.10. A stated number goes to the nearest bin for calibration only. Method › A · “In my view, mental health will be the largest market in healthcare within 10 years”
Base rateThe probability a published external study gives an event of that class and stage, fixed at intake. Halved when the item window is shorter than the class median time to decision. Never learned from the ledger's own items. Method ›
None in the table
Tags
retrospective
Coder BCohen's kappa: agreement between two coders beyond chance, from -1 to 1. Reported for admit, event, deadline, bin and asserts from the second-coder match test. Method ›
admittedA statement that passed intake: sincere, the person's own claim, forward-looking, inside the five areas, and not excluded by a reason code. Only admitted statements become items. Method › · event E-0104 · deadline 5 Jun 2035 · bin A
Registry entry

Global annual sales of mental health treatments exceed those of every other therapeutic area, including oncology and cardiology, per a named published therapeutic-area market series.

Resolved on the named data series only: the IQVIA Institute's global medicine spending by therapeutic area (Global Use of Medicines report). TRUE for the first reporting year in which the series ranks the mental health therapeutic area first by global spending, above oncology, cardiovascular and every other area. The rank is read from the series as published; when the series publishes no separate mental health line, its nearest mental health category is used and the reading is logged at intake. FALSE at the deadline when no published year ranks mental health first. If the series has not published 12 months after the deadline, the event is unresolvable. Realized values are stored, not scored.

Resolution source: IQVIA Institute, Global Use of Medicines (spending by therapeutic area)

Readings: 'The largest market in healthcare' is read as the largest therapeutic-area market for medicines, the comparison the forecaster himself makes ('surpassing oncology and cardiology'), not all healthcare spending.; 'Within 10 years' fixes the deadline on the item, not the event.; A rank of 1 in the named series is the threshold; no band applies, because the claim is a rank, not a point number.

How to read
The event, criterion and deadline were written at intake, before the outcome1 if the registry event happened on or before the item's deadline, 0 if it did not. Written by a resolver who never sees p. Method › was looked up. Coder B coded the statement independently.

Coder A

Resolution

State
PendingAn item whose deadline has not passed. Counted, never scored. Method ›
Effective deadlineAn item enters the score only when its deadline has passed and the outcome is true or false. A claim already known true still waits for its deadline. Method ›
5 Jun 2035
Outcome1 if the registry event happened on or before the item's deadline, 0 if it did not. Written by a resolver who never sees p. Method ›
not occurred · checked through 14 Sep 2026
Resolver note
The named series still ranks mental health well below first. The latest edition, Global Medicine Use Trends 2026 (published 2026-02-11), names oncology, immunology, diabetes and obesity as the leading therapy areas and the drivers of spending growth; no published year ranks mental health first. IQVIA's companion oncology report puts cancer medicine spending at USD 252 billion globally in 2024, rising to a forecast USD 441 billion by 2029, an order of magnitude above global mental health medicine spending. realized_value is null: the public summaries do not publish an exact numeric rank for the mental health line, only that it is not first. The series continues to publish, so the event is resolvable, not unresolvable.
BrierThe squared gap between a probability and the outcome, (p - o)^2. 0 is perfect, 0.25 is the constant coin flip, 1 is confidently wrong. Lower is better. Method ›
Not scored
How to read
State at window close; the outcome comes from the registry, the score from the rule.

Registry

Timeline

1 claim against 26 events in the field.

saiddueevent
16 Jun 2025 · Supernus Pharmaceuticals / Sage Therapeutics: Supernus agrees to acquire Sage Therapeutics (Zurzuvae) after Sage rebuffed Biog23 Jun 2025 · Compass Pathways: Compass shares fall sharply as investors judge the 3.6-point COMP005 effect size30 Jun 2025 · Cybin: Cybin announces a financing of up to $500M in convertible debentures to fund its20 Aug 2025 · Lykos Therapeutics: Lykos names former Point72 capital markets head Nick McEntire as president under28 Aug 2025 · Lykos Therapeutics / Resilient Pharmaceuticals: Lykos Therapeutics rebrands as Resilient Pharmaceuticals following the Gracias-l22 Oct 2025 · Mindbloom: A wrongful-death lawsuit is filed against at-home ketamine provider Mindbloom ov31 Oct 2025 · MindMed: MindMed closes an upsized underwritten public offering after positive phase 3 pl5 Nov 2025 · AtaiBeckley: atai and Beckley Psytech complete their combination to form AtaiBeckley; a $150M19 Nov 2025 · Done Global: A federal jury convicts Done founder Ruthia He and clinical president David Brod17 Dec 2025 · Done Global: A federal grand jury indicts Done Global itself over the alleged $100M Adderall 5 Jan 2026 · Cybin / Helus Pharma: Cybin rebrands as Helus Pharma and moves its US listing to Nasdaq under ticker H12 Jan 2026 · MindMed / Definium Therapeutics: MindMed rebrands as Definium Therapeutics (Nasdaq: DFTX from Jan 15) and guides 21 Jan 2026 · Johnson & Johnson (Spravato): J&J full-year 2025 results show Spravato sales of about $1.7B, with Q4 2025 up 618 Feb 2026 · Compass Pathways: Compass prices a $150M public offering the day after COMP006 topline; with warra1 Mar 2026 · Alto Neuroscience: Alto closes a $120M private placement led by Commodore Capital at $20 per share,17 Mar 2026 · Neuronetics: Neuronetics appoints Dan Reuvers as CEO as 2025 revenue nearly doubles after the7 Apr 2026 · Neuronetics: Neuronetics' top shareholder says the company has 'chronically underperformed' a29 Apr 2026 · GH Research: GH Research prices a $117.5M underwritten offering at $18 per share to fund the 13 May 2026 · Compass Pathways: Compass Q1 2026 update: rolling NDA sections already submitted, final submission25 Jun 2026 · Definium Therapeutics: Definium closes an upsized $805M public offering at $34 per share three days aft25 Jun 2026 · Helus Pharma: Helus completes a $50M underwritten offering, lifting cash to about $207M ahead 8 Jul 2026 · Done Global: Done founder Ruthia He is sentenced to 72 months in prison and fined $90M for th15 Jul 2026 · Johnson & Johnson (Spravato): J&J Q2 2026 results show Spravato sales of $584M, up 25% quarter over quarter an16 Jul 2026 · Eli Lilly / AtaiBeckley: Lilly agrees to acquire AtaiBeckley for $6.75 per share cash plus a CVR of up to3 Aug 2026 · Helus Pharma: Helus Pharma appoints Michael Halstead as chief executive officer ahead of its p11 Sep 2026 · Eli Lilly / AtaiBeckley: Eli Lilly completes its acquisition of AtaiBeckley, taking BPL-003 and VLS-01 inELI LILLY / ATAIBECKLEY: ELI LILLY COMPLETES ITS ACQUISITION OF ATAIBECKLEY, TAKING BPL-003 AND VLS-01 INMENTAL HEALTH BEC…Mental health becomes the largest therapeutic-area market in healthcare · stated 5 Jun 2025Mental health becomes the largest therapeutic-area market in healthcare · restated 5 Jun 2025 · p 90%90%TODAY20262028203020322034

Company and market outcomes